Product Description
an antibody to IL-13 for airway hyperresponsiveness and airway inflammation in mild asthmatics. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00725582)
Mechanisms of Action: IL13 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous,Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Asthma|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 3192K1-1002 | P1 |
Completed |
Asthma |
2009-06-01 |
2019-03-18 |
||
| 3192K1-1001 | P1 |
Completed |
Healthy Volunteers |
2008-11-01 |
2019-03-21 |
Treatments |
|
| 3192K1-1000 | P1 |
Completed |
Healthy Volunteers |
2008-07-01 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|